#28 AstraZeneca — Strategic Initiative & Reskilling | Global Intelligence Report 2024-2026

Revenue

$46B

2030 Target

$80B

Blockbusters

12 drugs

R&D Investment

£450M (Cambridge)

Key Strategic Initiative — Review 1: Restructuring Profile

Oncology + Rare Disease Growth Engine

R&D Portfolio Concentration Stage: Scaling

AstraZeneca concentrated on oncology (Tagrisso, Lynparza, Calquence, Enhertu), rare disease, and cardiovascular, achieving 12 blockbuster drugs by 2024 and targeting $80B revenue by 2030. Deployed AI-driven drug discovery (partnership with Recursion) and personalised medicine. Committed £450M to Cambridge UK R&D expansion.

Review 2: Reskilling Imperatives — Skill Gap Analysis

Scientific + Digital

Oncology biology & biomarkers

93%

AI drug discovery

90%

Precision oncology protocols

88%

Clinical data science

85%

Rare disease research methods

86%

ADC & bispecific therapeutics

84%

Affected Workforce Segments

Drug discovery scientistsClinical trial managersOncology specialistsAI researchers

Learning Infrastructure Required

AstraZeneca Global R&D Academy (Cambridge)
Partnership with Recursion for AI training
NHS collaboration for real-world evidence

Recommended Learning & Reskilling Modalities

1AstraZeneca Science Hub
2Oncology fellowship programs
3AI drug discovery certification
4Rare disease specialist training